New options for combination therapy for advanced non-squamous NSCLC

Area of Science:

• Oncology
• Immunotherapy
• Medical Oncology

Background:

• Nonsquamous non-small-cell lung cancer (NSCLC) comprises diverse subgroups, with the 'negative' subgroup (lacking oncogene addiction and high PD-L1 expression) being the most common.
• Historically, chemotherapy-based regimens (pemetrexed and/or bevacizumab) were standard for advanced nonsquamous NSCLC, yielding an overall survival of 12-17 months.
• The 'negative' subgroup represents approximately 50% of all new nonsquamous NSCLC diagnoses, highlighting the need for improved therapeutic strategies.

Purpose of the Study:

• To review emerging combination therapies for advanced nonsquamous non-oncogene-addicted NSCLC.
• To discuss recent clinical trial data and expert opinions on novel treatment options.
• To provide insights into the evolving landscape of first- and second-line treatments for this patient population.

Main Methods:

• A structured literature search of bibliographic databases for peer-reviewed research.
• Review of abstracts and data presented at major scientific meetings.
• Focused review question guiding the selection and discussion of relevant studies.

Main Results:

• First-line treatment options now include combinations of anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) with chemotherapy, irrespective of PD-L1 expression.
• Second-line treatment options have expanded to include combinations of antiangiogenic agents (ramucirumab, nintedanib) with docetaxel.
• These novel combinations represent significant advancements over traditional chemotherapy approaches for advanced nonsquamous NSCLC.

Conclusions:

• Combination therapies, including immunotherapy and antiangiogenic agents, are transforming the management of advanced nonsquamous non-oncogene-addicted NSCLC.
• First-line immunotherapy plus chemotherapy and second-line antiangiogenic combinations offer new hope and improved outcomes for patients.
• Further research is warranted to explore additional novel combinations and optimize treatment strategies for this prevalent NSCLC subgroup.